$QNRX SEC Filings

Filed On	Filing
26 Oct 2026	Form 4/A: Langer Dennis, Director Holds 49,687 shares of ADSs
20 Oct 2026	8-K: Regulation FD Disclosure; Other Events Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
14 Oct 2026	8-K: Regulation FD Disclosure; Other Events Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
07 Oct 2026	SCHEDULE 13G/A
02 Oct 2026	Proxy statement: special meeting on November 12, 2026
25 Sep 2026	EFFECT
25 Sep 2026	424B3
22 Sep 2026	PRE 14A
22 Sep 2026	8-K: Regulation FD Disclosure; Other Events First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy
18 Sep 2026	FORM S-3
10 Sep 2026	D
10 Sep 2026	8-K: Regulation FD Disclosure; Other Events FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome
01 Sep 2026	Form 4: Carter Denise P., Director Bought 20,490 shares ($100K) · Acquired 10,245 Ordinary Warrants (Right to Buy) (Open Market Purchase)
01 Sep 2026	Form 4: Myers Michael, Director Bought 20,490 shares ($100K) · Acquired 10,245 Ordinary Warrants (Right to Buy) (Open Market Purchase)
01 Sep 2026	Form 4: Lawlor Sally Bridget, Chief Financial Officer Bought 10,244 shares ($50K) · Acquired 5,122 Ordinary Warrants (Right to Buy) (Open Market Purchase)
01 Sep 2026	Form 4: Culverwell Anthony James, Director Bought 6,146 shares ($30K) · Acquired 3,073 Ordinary Warrants (Right to Buy) (Open Market Purchase)
28 Aug 2026	Form 4: Langer Dennis, Director Received 34,534 shares as a grant or award ($178K)
28 Aug 2026	Form 4: Culverwell Anthony James, Director Received 31,352 shares as a grant or award ($161K)
28 Aug 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
20 Aug 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more

Comments